Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO lands $268.4mm for Synageva

Executive Summary

Synageva BioPharma Corp. (orphan disease therapies) netted $268.4mm through the follow-on sale of 3mm common shares at $94.19. Some of the funds will help support the worldwide launch of Kanuma (sebelipase alfa) for lysosomal acid lipase (LAL) deficiency, begin a Phase I/II trial of its enzyme replacement therapy SBC103, and move preclinical SBC105 for rare disorders of calcification into the human studies.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies